Amendment: SEC Form SC 13G/A filed by Janux Therapeutics Inc.
$JANX
Biotechnology: Pharmaceutical Preparations
Health Care
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/3/2024 | $82.00 → $100.00 | Buy | BTIG Research |
| 12/3/2024 | $63.00 → $70.00 | Buy | H.C. Wainwright |
| 11/22/2024 | $79.00 | Outperform | Leerink Partners |
| 10/24/2024 | $69.00 | Buy | UBS |
| 9/6/2024 | $70.00 | Buy | Stifel |
| 5/30/2024 | $47.00 | Sector Perform | Scotiabank |
| 3/21/2024 | $62.00 | Buy | BTIG Research |
| 3/20/2024 | $100.00 | Overweight | Cantor Fitzgerald |
Ms. Doyle brings more than two decades of corporate strategy and business development experience across biotech, pharma, and venture ecosystems Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the appointment of Janeen Doyle, MBA, as Chief Corporate and Business Development Officer. "Janeen's unique blend of corporate development, strategic execution, and clinical insight makes her an ideal leader to help drive the next phase of growth at J
Phase 1b expansion study initiated with JANX007 in taxane-naïve mCRPC patients Updated JANX007 data from Phase 1a dose escalation support initiation of Phase 1b dose expansion Enrollment ongoing for JANX007 and JANX008 Updates on JANX007 and JANX008 expected in the second half of 2025 $1.01 billion in cash, cash equivalents, and short-term investments at end of first quarter 2025 Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today reported fina
Phase 1b expansion study initiated in taxane-naïve mCRPC patients Updated data from Phase 1a dose escalation support initiation of Phase 1b dose expansion Updates on JANX007 and JANX008 expected in the second half of 2025 Janux to host R&D Day in mid-2025 highlighting preclinical pipeline progression to the clinic Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the initiation of Phase 1b expansion studies in the ongoing ENGAGER-PSMA
BTIG Research reiterated coverage of Janux Therapeutics with a rating of Buy and set a new price target of $100.00 from $82.00 previously
H.C. Wainwright reiterated coverage of Janux Therapeutics with a rating of Buy and set a new price target of $70.00 from $63.00 previously
Leerink Partners initiated coverage of Janux Therapeutics with a rating of Outperform and set a new price target of $79.00
SCHEDULE 13G/A - Janux Therapeutics, Inc. (0001817713) (Subject)
10-Q - Janux Therapeutics, Inc. (0001817713) (Filer)
8-K - Janux Therapeutics, Inc. (0001817713) (Filer)
Ms. Doyle brings more than two decades of corporate strategy and business development experience across biotech, pharma, and venture ecosystems Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the appointment of Janeen Doyle, MBA, as Chief Corporate and Business Development Officer. "Janeen's unique blend of corporate development, strategic execution, and clinical insight makes her an ideal leader to help drive the next phase of growth at J
Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the promotion of Dr. Zachariah McIver to Chief Medical Officer. "The appointment of Zach to CMO is an important milestone for Janux. Zach's expertise in T cell engagers has brought significant value to our organization and he has been essential in our efforts to optimize the clinical development of our PSMA-TRACTr and clinical pipeline," said David Campbell, Ph.D., President and CEO of Janux.
The appointment of Eric Dobmeier and Natasha Hernday to the Board brings extensive operational and business development experience to support corporate and pipeline strategy Janux also announced the resignation of Jay Lichter, Ph.D., from the Board, and the appointment of current Board member Ronald W. Barrett, Ph.D., as Chairperson Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the appointment of Eric Dobmeier and Natasha Hernday to
4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
Multiple patients treated with PSMA-TRACTr JANX007 have achieved meaningful PSA drops coupled with manageable safety and CRS PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008 have been generally well tolerated at levels above the projected maximum tolerable dose of the parental T cell engagers JANX007 preliminary data showed encouraging safety results consistent with on-tumor activity with no dose-limiting toxicities PK exposure demonstrated TRACTr activation with lack of TCE accumulation No treatment-emergent ADA titers observed Janux to host virtual investor event today at 4:00 PM Eastern Time Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutica
SC 13G/A - Janux Therapeutics, Inc. (0001817713) (Subject)
SC 13G/A - Janux Therapeutics, Inc. (0001817713) (Subject)
SC 13G/A - Janux Therapeutics, Inc. (0001817713) (Subject)